ASX:BXN
Bioxyne Ltd
Investment Summary
The fund managers believe Bioxyne Ltd presents a unique investment opportunity as the company is positioned in the growing medical cannabis space. They note that the financial results have been outstanding and have largely gone unnoticed by local investors. According to the fund managers, Bioxyne's subsidiary, Breath Life Sciences, achieved a significant milestone by becoming the first TGA-licensed entity in Australia for manufacturing consumer CBD and THC products. In their opinion, the recent $7 million manufacturing and supply agreement with NectarTek further demonstrates Bioxyne's potential for growth and market acceptance. Overall, the fund managers express confidence in the value overlooked by the market, suggesting that Bioxyne may be undervalued at its current share price of approximately $0.03.
Commentary From The Managers
Cyan Investment Management
31 Mar 2025
$0.03
- Investment in Bioxyne Ltd (BXN), an Australian life sciences company.
- Focus on consumer health products in the expanding medical cannabis sector.
- Cyan Investment Management acknowledged strong financial results from BXN that have been overlooked by local investors.
- Belief that the market has underestimated the value generated by Bioxyne.
- Highlighting the significance of Breath Life Sciences, their subsidiary, as the first TGA-licensed manufacturer of CBD and THC products in Australia.
- Recent $7m manufacturing and supply agreement with NectarTek for consumer products supports the investment thesis.
Please note: The completeness, accuracy or current status of the investments referenced are not guaranteed.